US public offering
argenx
Co-managerKempen is pleased to announce that it acted as Co-Manager to argenx in its USD 301 million public offering
Transaction highlights
- The transaction comprised of 3,475,000 American Depositary Shares (ADSs) at a price of USD 86,50 per ADS. Each ADS represents the right to receive one ordinary share
- Gross proceeds amount to USD 301 million and will be used to, amongst others, fund the late stage clinical and commercial development of efgartigimod (ARGX-113) for the treatment of MG and ITP, start a Phase 2 clinical trial with efgartigimod in CIDP and advance the development of ARGX-117
- Gross proceeds could grow to c.USD 346m in case the option to purchase additional ADSs is exercised in full
- Kempen generated significant interest from US and European Life Sciences specialists, on top of European tier 1 generalist long-only investors which generated substantial demand in the bookbuilding exercise
- This is the second US offering in which Kempen acted as an underwriter after obtaining the license to do so less than two months ago, marking Kempen’s nineth Life Sciences transaction this year and the third US Life Sciences ECM transaction in little more than a week
- Kempen acted as Joint Global Coordinator and Joint Bookrunner in argenx’ IPO on Euronext in 2014 and has advised argenx on its NASDAQ IPO in May 2017 as well as subsequent US public offering in December 2017. Next to that, Kempen has been the number one broker in the stock ever since the 2014 IPO
Company description
argenx is a clinical stage biotechnology company, that develops a deep pipeline of differentiated antibody-based therapeutics for the treatment of severe autoimmune diseases and cancer. It discovers and develops
antibodies through its SIMPLE Antibody™ Platform based on the llama immune system and its three proprietary antibody engineering technologies. argenx’ lead product candidates include efgartigimod (ARGX-113), wich has shown positive Phase 2 proof of concept data for the treatment of autoimmune diseases myasthenia gravis (MG) and immune thrombocytopenia (ITP) and is also in Phase 2 development for autoimmune disease pemphigus vulgaris; and ARGX-110, currently in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma and acute myeloid leukemia. Also ARGX-110 has recently shown encouraging safety and efficacy data during an interim analysis of its Phase 1/2 trial. argenx was founded in 2008 and is listed on Euronext Brussels since 2014 and on NASDAQ since May 2017.
Contact
Read more on:
Transactions
No transactions found
Initial Public Offering on NASDAQ
Secondary placing of Fagron shares
Rights issue
a subsidiary of
Sale of German DIY portfolio to REDOS acting on behalf of Union Investment
Accelerated bookbuild offering
Accelerated Bookbuild Offering on behalf of selling shareholders in
Three-day bookbuild offering
Rights issue
Initial Public Offering
Accelerated Bookbuild Offering
Block trade in argenx shares
a subsidiary of
Sale of German retail portfolio to a real estate private equity firm
Sale of Dutch residential portfolio managed by
on behalf of investors to
Sale of
to
Bencis Capital Partners
Initial Public Offering
Capital increase
Block trade in ERYTECH shares
Initial public offering
Accelerated bookbuild offering
Initial public offering
Acquisition of
Block trade in Boskalis shares
US public offering
US public offering
Sale to
US public offering
Sale of Rabo Bouwfonds CIF datacenter portfolio
to
Initial public offering
Acquisition of former Delta Lloyd portfolio from
Rights issue
Public offer for
Accelerated bookbuild offering
Fundraise
Public offer by German ADLER Real Estate
for Israeli
Public offer by German Vonovia
Sale of Dynamic Portfolios
Public offer by Spanish Colonial
for Spanish Axiare Real Estate
Accelerated bookbuild offering
Sale of 3 German residential portfolios by Angelo Gordon
to consortium of buyers
Accelerated bookbuild offering
US public offering
Accelerated bookbuild offering
Secondary offering
Accelerated bookbuild offering
Accelerated bookbuild offering
Acquisition by
of
Acquisition of
by
Private placement
Acquisition by
of
Dutch wealth management activities
Acquisition by
of
from
Accelerated bookbuild offering
Initial public offering on NASDAQ
Share buy-back program
Acquisition by
of
Accelerated bookbuild offering
Secondary placement of 9.4% stake in
Public offer by
for
Public offer by German Vonovia
For Austrian Conwert
Secondary placement of 15% stake in
Formation of Passoã joint venture with
Accelerated bookbuild offering
Rights issue
Sale of 19% stake in
Accelerated bookbuild offering
Acquisition of the North American rights to RUCONEST by
from
Acquisition by
of
from
Strategic study
Secondary placement 30% stake in
Share buy-back program
Direct share placement
Private placement
Strategic study
Sale of the European veterinary business of
to
Strategic study
Private placement
Placement of treasury shares
Public offer for Deutsche Office
By German Alstria
Public offer for
Initial public offering
Rights issue
Rights issue
Initial public offering
Rights issue
Sale of
to
Residential portfolio sale by Dekor
A company owned by Reggeborgh
Rights issue
Accelerated bookbuild offering
Secondary placement of 35% stake in IOW
Accelerated bookbuild offering
Refinancing
Rights issue
Refinancing
Capital Raise
Initial public offering
Acquisition by
of
Refinancing
Initial Public Offering
Initial public offering
Rights issue
On behalf of
Acquisition of
Rights issue
Acquisition of French shopping centre portfolio by Wereldhave
From French-Dutch Unibail-Rodamco
Refinancing
Acquisition of the cancer immunotherapy program by
from
Initial public offering
Initial public offering
Public offer by French Groupe SMABTP
For French Société de la Tour Eiffel
Acquisition of
by
Secondary listing on Euronext Paris
Initial public offering
Acquisition by
of
Accelerated bookbuild offering
Convertible bond issue
Fairness opinion in the public offer by
Sale of Hercules business to ZEG
Refinancing
Convertible bond issue
Initial public offering
Sale of Dutch supply assets to
Accelerated bookbuild, preference shares issue and refinancing
Acquisition of
by
undisclosed PE firm
from
At-market rights issue
Acquisition by
of
Accelerated bookbuild offering
Private placement by acquisition vehicle for French Carrefour
Secondary offering
Combined offering of primary and secondary shares
Public offer for German listed GSW
by German listed
Initial Public Offering
Equity issue
Refinancing
Sale of majority of shares to
Accelerated bookbuild offering
Initial public offering
Secondary offering
Accelerated bookbuild offering
Public offer by
for
Private placement
Public offer by
for
Rights issue
